This HTML5 document contains 39 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n7http://linked.opendata.cz/ontology/domain/vavai/cep/druhSouteze/
n14http://linked.opendata.cz/ontology/domain/vavai/cep/zivotniCyklusProjektu/
n6http://linked.opendata.cz/ontology/domain/vavai/cep/typPojektu/
dctermshttp://purl.org/dc/terms/
n2http://linked.opendata.cz/resource/domain/vavai/projekt/
n13http://linked.opendata.cz/resource/domain/vavai/subjekt/
n8http://linked.opendata.cz/resource/domain/vavai/cep/prideleniPodpory/
n18http://linked.opendata.cz/ontology/domain/vavai/cep/kategorie/
n10http://linked.opendata.cz/ontology/domain/vavai/
n21http://linked.opendata.cz/ontology/domain/vavai/cep/duvernostUdaju/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
n15http://linked.opendata.cz/ontology/domain/vavai/cep/fazeProjektu/
n9http://linked.opendata.cz/ontology/domain/vavai/cep/obor/
n19http://linked.opendata.cz/ontology/domain/vavai/cep/statusZobrazovaneFaze/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
xsdhhttp://www.w3.org/2001/XMLSchema#
n4http://linked.opendata.cz/ontology/domain/vavai/cep/
n20http://linked.opendata.cz/resource/domain/vavai/projekt/7E12076/
n17http://linked.opendata.cz/resource/domain/vavai/cep/vyzva/
n12http://linked.opendata.cz/resource/domain/vavai/aktivita/
n11http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:7E12076
rdf:type
n10:Projekt
rdfs:seeAlso
http://www.isvav.cz/projectDetail.do?rowId=7E12076 http://www.optimisetrial.eu/
dcterms:description
The study is an international multicentric collaborative trial. This study will focus on two goals: optimising current treatments in schizophrenia and explore novel therapeutic options for schizophrenia. The study intends to both address basic, but so far unanswered, questions in the treatment of schizophrenia and develop new interventions. It is expected that the project will lead to evidence that is directly applicable to treatment guidelines, and will identify potential mechanisms for new drug development. Objectives: I To test applicability of amisulpride as the first step in a treatment algorithm. II To test guideline recommendation that non-responders to an antipsychotic drug benefit from a switch to an antipsychotic with a different receptor binding profile. III To provide the acceptability and outcome data on the application of clozapine in non-responding patients within the first 10 weeks of their treatment initiation. IV To test if an IT-enabled psychosocial intervention can improve treatment adherence and global functional outcome in symptomatically remitted first-episode schizophrenia patients. V To test whether glutamatergic markers predict response to first and second line treatments. VI To test if a combination of pharmacogenetic, proteomics- and metabolomic markers can provide clinical valuable predictive value. VII To define the nature and prevalence of ’organic’ pathology in patients presenting with a first episode schizophreniform psychosis VIII To determine the extent to which MRI measures at first presentation predict the therapeutic response to subsequent antipsychotic treatment. The study is an international multicentric collaborative trial. This study will focus on two goals: optimising current treatments in schizophrenia and explore novel therapeutic options for schizophrenia. The study intends to both address basic, but so far unanswered, questions in the treatment of schizophrenia and develop new interventions. It is expected that the project will lead to evidence that is directly applicable to treatment guidelines, and will identify potential mechanisms for new drug development. Objectives: I To test applicability of amisulpride as the first step in a treatment algorithm. II To test guideline recommendation that non-responders to an antipsychotic drug benefit from a switch to an antipsychotic with a different receptor binding profile. III To provide the acceptability and outcome data on the application of clozapine in non-responding patients within the first 10 weeks of their treatment initiation. IV To test if an IT-enabled psychosocial intervention can improve treatment adherence and global functional outcome in symptomatically remitted first-episode schizophrenia patients. V To test whether glutamatergic markers predict response to first and second line treatments. VI To test if a combination of pharmacogenetic, proteomics- and metabolomic markers can provide clinical valuable predictive value. VII To define the nature and prevalence of ’organic’ pathology in patients presenting with a first episode schizophreniform psychosis VIII To determine the extent to which MRI measures at first presentation predict the therapeutic response to subsequent antipsychotic treatment.
dcterms:title
OPTiMiSE Optimization of Treatment and Management of Schizophrenia in Europe OPTiMiSE Optimization of Treatment and Management of Schizophrenia in Europe (Optimalizace léčby a postupu léčby schizofrenie v Evropě)
skos:notation
7E12076
n4:aktivita
n12:7E
n4:celkovaStatniPodpora
n20:celkovaStatniPodpora
n4:celkoveNaklady
n20:celkoveNaklady
n4:datumDodatniDoRIV
2015-02-16+01:00
n4:druhSouteze
n7:RP
n4:duvernostUdaju
n21:S
n4:fazeProjektu
n15:100527304
n4:hlavniObor
n9:FL
n4:kategorie
n18:AP
n4:klicovaSlova
schizophrenia; antipsychotic; treatment response; psychosocial intervention
n4:partnetrHlavni
n13:ico%3A00023752
n4:pocetKoordinujicichPrijemcu
0
n4:pocetPrijemcu
1
n4:pocetSpoluPrijemcu
0
n4:pocetVysledkuRIV
0
n4:pocetZverejnenychVysledkuVRIV
0
n4:posledniUvolneniVMinulemRoce
2013-03-20+01:00
n4:prideleniPodpory
n8:MSMT-1840%2F2013-310
n4:sberDatUcastniciPoslednihoRoku
n11:2014
n4:sberDatUdajeProjZameru
n11:2014
n4:statusZobrazovaneFaze
n19:DRRVK
n4:typPojektu
n6:P
n4:ukonceniReseni
2014-02-28+01:00
n4:vedlejsiObor
n9:EA n9:EB
n4:zahajeniReseni
2012-03-01+01:00
n4:zivotniCyklusProjektu
n14:ZBK
n4:vyzva
n17:FP7-INCO-2013-1
n4:klicoveSlovo
antipsychotic treatment response schizophrenia